These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
855 related articles for article (PubMed ID: 30274202)
1. Molecular Mechanisms of Hepatocarcinogenesis Following Sustained Virological Response in Patients with Chronic Hepatitis C Virus Infection. Hayes CN; Zhang P; Zhang Y; Chayama K Viruses; 2018 Sep; 10(10):. PubMed ID: 30274202 [TBL] [Abstract][Full Text] [Related]
2. Differences in background characteristics of patients with chronic hepatitis C who achieved sustained virologic response with interferon-free versus interferon-based therapy and the risk of developing hepatocellular carcinoma after eradication of hepatitis C virus in Japan. Toyoda H; Tada T; Takaguchi K; Senoh T; Shimada N; Hiraoka A; Michitaka K; Ishikawa T; Kumada T J Viral Hepat; 2017 Jun; 24(6):472-476. PubMed ID: 27983762 [TBL] [Abstract][Full Text] [Related]
3. Long-term effect of sustained virological response on hepatocellular carcinoma in patients with hepatitis C in Canada. Janjua NZ; Chong M; Kuo M; Woods R; Wong J; Yoshida EM; Sherman M; Butt ZA; Samji H; Cook D; Yu A; Alvarez M; Tyndall M; Krajden M J Hepatol; 2017 Mar; 66(3):504-513. PubMed ID: 27818234 [TBL] [Abstract][Full Text] [Related]
4. Hepatocellular Carcinoma Incidences and Risk Factors in Hepatitis C Patients: Interferon versus Direct-Acting Agents. Kao YT; Liu YC; Cheng YT; Wen YW; Hsieh YC; Hsu CE; Su CW; Tai JC; Chen YC; Jeng WJ; Lin CY; Chien RN; Tai DI; Sheen IS Viruses; 2024 Sep; 16(9):. PubMed ID: 39339961 [TBL] [Abstract][Full Text] [Related]
5. The development of hepatocellular carcinoma in HCV-infected patients treated with DAA: A comprehensive analysis. Huang P; Liu M; Zang F; Yao Y; Yue M; Wang J; Fan H; Zhuo L; Wu J; Xia X; Feng Y; Yu R Carcinogenesis; 2018 Dec; 39(12):1497-1505. PubMed ID: 30602007 [TBL] [Abstract][Full Text] [Related]
6. Sustained virologic response to direct-acting antiviral agents predicts better outcomes in hepatitis C virus-infected patients: A retrospective study. Colussi G; Donnini D; Brizzi RF; Maier S; Valenti L; Catena C; Cavarape A; Sechi LA; Soardo G World J Gastroenterol; 2019 Oct; 25(40):6094-6106. PubMed ID: 31686765 [TBL] [Abstract][Full Text] [Related]
7. The impact of treatment of hepatitis C with DAAs on the occurrence of HCC. Roche B; Coilly A; Duclos-Vallee JC; Samuel D Liver Int; 2018 Feb; 38 Suppl 1():139-145. PubMed ID: 29427487 [TBL] [Abstract][Full Text] [Related]
8. The impact of interferon-free direct-acting antivirals on clinical outcome after curative treatment for hepatitis C virus-associated hepatocellular carcinoma: Comparison with interferon-based therapy. Nagaoki Y; Imamura M; Nishida Y; Daijo K; Teraoka Y; Honda F; Nakamura Y; Morio K; Fujino H; Nakahara T; Kawaoka T; Tsuge M; Hiramatsu A; Kawakami Y; Miki D; Hiyama Y; Ochi H; Chayama K; Aikata H J Med Virol; 2019 Apr; 91(4):650-658. PubMed ID: 30381831 [TBL] [Abstract][Full Text] [Related]
9. Stagnation of histopathological improvement is a predictor of hepatocellular carcinoma development after hepatitis C virus eradication. Motoyama H; Tamori A; Kubo S; Uchida-Kobayashi S; Takemura S; Tanaka S; Ohfuji S; Teranishi Y; Kozuka R; Kawamura E; Hagihara A; Morikawa H; Enomoto M; Murakami Y; Kawada N PLoS One; 2018; 13(3):e0194163. PubMed ID: 29534101 [TBL] [Abstract][Full Text] [Related]
10. Hepatocarcinogenesis Is Associated with Serum Albumin Levels after Sustained Virological Responses with Interferon-Based Therapy in Patients with Hepatitis C. Umehara Y; Hagiwara S; Nishida N; Sakurai T; Ida H; Minami Y; Takita M; Minami T; Chishina H; Ueshima K; Komeda Y; Arizumi T; Watanabe T; Kudo M Dig Dis; 2017; 35(6):548-555. PubMed ID: 29040987 [TBL] [Abstract][Full Text] [Related]
11. Direct-acting antivirals and hepatocellular carcinoma in chronic hepatitis C: A few lights and many shadows. Guarino M; Sessa A; Cossiga V; Morando F; Caporaso N; Morisco F; World J Gastroenterol; 2018 Jun; 24(24):2582-2595. PubMed ID: 29962815 [TBL] [Abstract][Full Text] [Related]
12. Risk of hepatocellular carcinoma occurrence after antiviral therapy for patients with chronic hepatitis C Infection: a systematic review and meta-analysis. Lv GJ; Ji D; Yu L; Chen HY; Chen J; He M; Wang WC; Wang HB; Tsang C; Wang J; Yu ML; Lau G; Hepatol Int; 2024 Oct; 18(5):1459-1471. PubMed ID: 38965190 [TBL] [Abstract][Full Text] [Related]
13. Risk of Hepatocellular Cancer in HCV Patients Treated With Direct-Acting Antiviral Agents. Kanwal F; Kramer J; Asch SM; Chayanupatkul M; Cao Y; El-Serag HB Gastroenterology; 2017 Oct; 153(4):996-1005.e1. PubMed ID: 28642197 [TBL] [Abstract][Full Text] [Related]
14. Direct-acting antiviral agents do not increase the incidence of hepatocellular carcinoma development: a prospective, multicenter study. Ide T; Koga H; Nakano M; Hashimoto S; Yatsuhashi H; Higuchi N; Nakamuta M; Oeda S; Eguchi Y; Shakado S; Sakisaka S; Yoshimaru Y; Sasaki Y; Honma Y; Harada M; Seike M; Maeshiro T; Miuma S; Nakao K; Mawatari S; Ido A; Nagata K; Matsumoto S; Takami Y; Sohda T; Kakuma T; Torimura T Hepatol Int; 2019 May; 13(3):293-301. PubMed ID: 30820753 [TBL] [Abstract][Full Text] [Related]
15. Development of hepatocellular carcinoma in patients with hepatitis C virus infection who achieved sustained virological response following interferon therapy: A large-scale, long-term cohort study. Nagaoki Y; Aikata H; Nakano N; Shinohara F; Nakamura Y; Hatooka M; Morio K; Kan H; Fujino H; Kobayashi T; Fukuhara T; Masaki K; Ono A; Nakahara T; Kawaoka T; Miki D; Tsuge M; Hiramatsu A; Imamura M; Takahashi S; Kawakami Y; Ochi H; Chayama K; J Gastroenterol Hepatol; 2016 May; 31(5):1009-15. PubMed ID: 26584407 [TBL] [Abstract][Full Text] [Related]
16. The short-term incidence of hepatocellular carcinoma is not increased after hepatitis C treatment with direct-acting antivirals: An ERCHIVES study. Li DK; Ren Y; Fierer DS; Rutledge S; Shaikh OS; Lo Re V; Simon T; Abou-Samra AB; Chung RT; Butt AA Hepatology; 2018 Jun; 67(6):2244-2253. PubMed ID: 29205416 [TBL] [Abstract][Full Text] [Related]
17. Incidence of Hepatocellular Carcinoma in Patients With HCV-Associated Cirrhosis Treated With Direct-Acting Antiviral Agents. Calvaruso V; Cabibbo G; Cacciola I; Petta S; Madonia S; Bellia A; Tinè F; Distefano M; Licata A; Giannitrapani L; Prestileo T; Mazzola G; Di Rosolini MA; Larocca L; Bertino G; Digiacomo A; Benanti F; Guarneri L; Averna A; Iacobello C; Magro A; Scalisi I; Cartabellotta F; Savalli F; Barbara M; Davì A; Russello M; Scifo G; Squadrito G; Cammà C; Raimondo G; Craxì A; Di Marco V; Gastroenterology; 2018 Aug; 155(2):411-421.e4. PubMed ID: 29655836 [TBL] [Abstract][Full Text] [Related]
18. The impact of HCV eradication by direct-acting antivirals on the transition of precancerous hepatic nodules to HCC: A prospective observational study. Toyoda H; Kumada T; Tada T; Mizuno K; Sone Y; Akita T; Tanaka J; Johnson PJ Liver Int; 2019 Mar; 39(3):448-454. PubMed ID: 30312003 [TBL] [Abstract][Full Text] [Related]
19. Sustained virologic response by direct antiviral agents reduces the incidence of hepatocellular carcinoma in patients with HCV infection. Kobayashi M; Suzuki F; Fujiyama S; Kawamura Y; Sezaki H; Hosaka T; Akuta N; Suzuki Y; Saitoh S; Arase Y; Ikeda K; Kumada H J Med Virol; 2017 Mar; 89(3):476-483. PubMed ID: 27531586 [TBL] [Abstract][Full Text] [Related]
20. The impact of SVR from direct-acting antiviral- and interferon-based treatments for HCV on hepatocellular carcinoma risk. Janjua NZ; Wong S; Darvishian M; Butt ZA; Yu A; Binka M; Alvarez M; Woods R; Yoshida EM; Ramji A; Feld J; Krajden M J Viral Hepat; 2020 Aug; 27(8):781-793. PubMed ID: 32187430 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]